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Introduction: Paradoxically, a breast cancer risk reduction with conjugated equine estrogens (CEE) and a risk
elevation with CEE plus medroxyprogesterone acetate (CEE + MPA) were observed in the Women’s Health Initiative
(WHI) randomized controlled trials. The effects of hormone therapy on serum sex hormone levels, and on the
association between baseline sex hormones and disease risk, may help explain these divergent breast cancer
findings.
Methods: Serum sex hormone concentrations were measured for 348 breast cancer cases in the CEE + MPA trial
and for 235 cases in the CEE trial along with corresponding pair-matched controls, nested within the WHI trials of
healthy postmenopausal women. Association and mediation analyses, to examine the extent to which sex hormone
levels and changes can explain the breast cancer findings, were conducted using logistic regression.
Results: Following CEE treatment, breast cancer risk was associated with higher concentrations of baseline serum
estrogens, and with lower concentrations of sex hormone binding globulin. However, following CEE + MPA, there
was no association of breast cancer risk with baseline sex hormone levels. The sex hormone changes from baseline
to year 1 provided an explanation for much of the reduced breast cancer risk with CEE. Specifically, the treatment
odds ratio (95% confidence interval) increased from 0.71 (0.43, 1.15) to 0.92 (0.41, 2.09) when the year 1 measures
were included in the logistic regression analysis. In comparison, the CEE + MPA odds ratio was essentially
unchanged when these year 1 measures were included.
Conclusions: Breast cancer risk remains low following CEE use among women having favorable baseline sex
hormone profiles, but CEE + MPA evidently produces a breast cancer risk for all women similar to that for women
having an unfavorable baseline sex hormone profile. These patterns could reflect breast ductal epithelial cell
stimulation by CEE + MPA that is substantially avoided with CEE, in conjunction with relatively more favorable
effects of either regimen following a sustained period of estrogen deprivation. These findings may have
implications for other hormone therapy formulations and routes of delivery.
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The Women’s Health Initiative (WHI) randomized, placebo-
controlled postmenopausal hormone therapy (HT) trials
were instrumental in leading to changes in clinical prac-
tice, including much reduced use of HT in the U.S. and
around the world. Among the most important reasons for
this change was the substantial elevation in breast cancer
risk [1-4] among women assigned to active hormones in
the CEE +MPA trial. In contrast, a modest reduction in
breast cancer incidence [5-7] was observed among women
assigned to active hormones in the CEE trial.
Considerable effort has been devoted to understanding
these divergent breast cancer findings, through investiga-
tion of hazard ratio (HR) variations among trial cohort
subsets [2,6] and through comparisons of HRs with those
from the companion WHI Observational Study. The latter
analyses reveal higher HRs among women who started
HT soon after menopause [8,9], as has also been observed
in other cohorts, for example, Beral et al. [10]. A recent
report provides a detailed side-by-side presentation of
CEE +MPA and CEE effects on breast cancer and other
outcomes during the intervention and post-intervention
phases of the WHI trials [11].
Serum sex hormone concentrations changed markedly
following CEE or CEE +MPA administration in the WHI
trial cohorts, with an approximate doubling of estradiol,
estrone sulphate and sex hormone binding globulin
(SHBG), and an approximate tripling of estrone with ac-
tive treatment in each trial [12]. A recent report on a
breast cancer nested case-control study within the CEE +
MPA trial cohort noted that the treatment odds ratio was
appreciably larger for women having relatively low base-
line serum estrogens. For example, the OR (95% confi-
dence interval (CI)) for breast cancer with CEE +MPA
treatment was 2.47 (1.28, 4.79) among women in the low-
est estradiol quartile, compared to 0.96 (0.44, 2.04) in the
highest quartile [13].
Here we follow-up on this intriguing observation by
examining the association between baseline serum sex
hormones in the CEE +MPA and CEE trials and breast
cancer risk, separately in the active treatment and placebo
groups, during the intervention phases of the WHI trials.
Concurrent associations of sex hormone changes from
baseline to one year following randomization are also
considered, and mediation analyses are conducted to
examine the extent to which sex hormone changes can
provide an explanation for the breast cancer findings in
the two WHI trials.
Methods
Study population: breast cancer cases and controls
The design of the WHI Clinical Trial (CT) and corre-
sponding baseline enrollee characteristics have been pre-
sented [14,15]. All women were postmenopausal and inthe age range 50 to 79 when enrolled at 40 U.S. clinical
centers during 1993 to 1998. The CT enrolled 68,132
women to either or both of a hormone therapy trial
(27,347 women) or a low-fat dietary pattern trial (48,835
women). The CEE +MPA trial randomly assigned 16,608
women with uterus to 0.625 mg/d oral CEE plus con-
tinuous 2.5 mg/d MPA, or matching placebo. The CEE
trial randomly assigned 10,739 women who were post-
hysterectomy to this same oral estrogen preparation or
placebo.
Women were excluded from the HT trials for breast
cancer or other prior cancer (except non-melanoma skin
cancer) within the past 10 years, baseline mammogram
or clinical breast exam suggestive of cancer, or predicted
survival of less than three years.
Women having ongoing or recent HT use at screening
required a three-month washout period before becoming
eligible.
The CEE +MPA trial intervention phase stopped early
in July 2002, following an average of 5.6 years of inter-
vention, when it was judged that health risks exceeded
benefits. An elevation in breast cancer risk, in conjunc-
tion with an unfavorable global health risk versus benefit
index, was key to the early stopping decision [1]. The
CEE trial also stopped early in February 2004, primarily
because of a stroke elevation of similar magnitude to
that for CEE +MPA, following an average 7.1 years of
intervention [5].
Clinical outcomes [16] were reported semi-annually in
the CT through the end of the intervention period by
self-administered questionnaires. Invasive breast cancer
occurrences were confirmed by review of medical re-
cords and pathology reports by physician-adjudicators at
local clinical centers. These events were classified cen-
trally using NCI’s Surveillance, Epidemiology, and End
Results coding system, including coding of histology,
hormone receptor status and HER2 over-expression.
All women provided written informed consent for their
various components of WHI participation, and for their
participation in the postmenopausal hormone therapy
randomized controlled trials. The protocol and informed
consent documents and procedures were approved by the
Institutional Review Board (IRB) of the Fred Hutchinson
Cancer Research Center, and by the IRBs of each of the
participating clinical centers. All research was conducted
in compliance with the Helsinki Declaration.
There were 348 and 235 (invasive) breast cancer cases
having sufficient serum for sex hormone analyses during
the intervention phases of the CEE +MPA and CEE trials,
respectively. Each was matched to a control from the
same trial cohort who was without breast cancer during
the trial intervention phase, on age at screening (within
one year), race (white, black, Hispanic, other) and date of
randomization (within 30 days).
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sex hormones
Blood samples were collected at baseline and year 1 after
an overnight fast of at least 12 hours [17]. Specimens were
separated and stored at -70°C within two hours of collec-
tion prior to shipping to a central repository. Baseline and
one-year serum specimens from a case and matched con-
trol were batched together, and sent to the Reproductive
Endocrine Research Laboratory (University of Southern
California, Los Angeles, CA, USA) for sex hormone assess-
ment. Laboratory personnel were blinded to case versus
control status, and to baseline versus one-year collections.
Total estradiol and estrone concentrations were quantified
by radioimmunoassays (RIA) using methods previously\-
described [13]. Estrone sulfate was measured by direct RIA
using a commercial kit (Beckman Coulter, Minneapolis,
MN, USA). SHBG was quantified by use of a direct
chemiluminescent immunoassay using the Immulite
Analyzer (Siemens Medical Solutions Diagnostics, Mal-
vern, PA, USA). Bioavailable (non-SHBG-bound) estradiol
concentration was calculated by an algorithm that uses
the total estradiol and SHBG measurements [13].
Split sample quality control specimens, derived from
women who were screened for WHI participation but
did not enroll, were included in each assay batch. There
were 60 such samples selected for the baseline hormone
assays, and 60 for the year 1 assays in this case-control
study. The quality control specimens revealed substantial
variations between blind duplicate samples for a small
fraction of pairs, particularly at low concentrations.
However, the intra-assay coefficients of variation for
the various assays were acceptable, and ranged from
4.2% to 13.4%, after excluding outliers that had differ-
ences between duplicates following log-transformation
that exceeded twice the interquartile range (IQR). The
assay sensitivities for estradiol, estrone, estrone sulfate
and SHBG were 2, 4 and 50 pg/ml, and 1 Nmol/L, re-
spectively.Study subjects were excluded from analyses
for each analyte if one or both of the baseline and year 1
assessments did not yield a measurement. The number of
individuals excluded in the CEE +MPA trial was 49 for es-
tradiol, 61 for bioavailable estradiol, 49 for estrone, 105
for estrone sulfate and 46 for SHBG. The corresponding
numbers for the CEE trial were 35, 43, 33, 85 and 36.
Statistical methods
Serum hormone measurements were log-transformed to
achieve approximate normal distributions. In response
to the split sample blind duplicate data mentioned above,
cases or controls were excluded for a specific analyte if
the logarithm of the ratio of one-year to baseline values
was outside of the 25th to 75th percentiles of the data
by more than twice the IQR, separately by trial and
randomization group.OR modeling relied on logistic regression with case (1)
or control (0) defining the binary ‘response’ variable [18].
Odds ratios were estimated as a function of (log-trans-
formed) baseline and year 1 concentrations. For ease of
interpretation, ORs corresponding to a doubling of the
serum hormone concentrations are presented. Medi-
ation was assessed by comparing the post-year 1 breast
cancer OR associated with hormone therapy when only
baseline serum hormones were included in the model,
to the corresponding hormone therapy OR when year 1
serum hormone concentrations, or equivalently the ra-
tio of year 1 to baseline concentrations, were added to
the OR model. Mediation is indicated by hormone ther-
apy ORs that move substantially toward the null when
the year 1 analyte data are included. In addition to the
matching factors of age and race, the logistic regression
analyses included baseline body mass index (BMI), family
history of breast cancer, cigarette smoking history and
Gail model five-year breast cancer risk score [19] as
control variables.
Nominal 95% CIs are presented for odds ratios, and all
significance levels (P-values) are two-sided.
Results
Table 1 presents distributional information for breast
cancer cases and controls, separately for the CEE and
CEE +MPA trials, in relation to several baseline charac-
teristics. The average age for cases was about 64 years,
and average BMI was about 30.
Subsequent analyses exclude 31 breast cancer cases in
the CEE +MPA trial and 16 cases in the CEE trial that
occurred during the first year from randomization. The
log-transformed ratios of year 1 to baseline values had
approximately normal distributions for each sex hor-
mone, but with a small fraction of outlying values, as an-
ticipated from the blind duplicate data. Applying the
interquartile range criterion (see Methods) led to the
further exclusion of the following number of placebo
cases or controls in the CEE +MPA trial: estradiol - 20,
bioavailable estradiol - 25, estrone - 25, estrone sulfate -
28, SHBG - 21. Corresponding numbers in the active
treatment group in the CEE +MPA trial were 11, 19, 11, 7
and 10; with the smaller number of exclusions consistent
with the notion that measurement reliability is primarily an
issue at low concentrations. The corresponding numbers of
cases or controls excluded from the CEE trial placebo
group on the basis of this IQR criterion were 31, 30, 17, 16
and 31, and from the CEE trial active treatment group were
9, 10, 5, 10 and 3.
Tables 2 and 3 show geometric means and 95% confi-
dence intervals for cases and controls for each analyte,
separately for the placebo and active groups in the CEE +
MPA trial and the CEE trial. In the placebo group in
either trial one sees the expected positive association
Table 1 Mean ± SE for continuous baseline covariates, and number (%) for categorical baseline covariates for breast
cancer cases and controls occurring during the intervention phases of the Women’s Health Initiative CEE +MPA and
CEE trials
CEE +MPA trial CEE trial
Cases Controls P-value* Cases Controls P-value*
N 348 348 235 235
Age† 64.32 ± 6.85 64.33 ± 6.82 0.98 64.5 ± 7.11 64.49 ± 7.06 0.97
BMI 29.33 ± 5.56 28.46 ± 5.69 0.04 31.46 ± 5.98 29.32 ± 5.70 <0.01
Gail model five-year risk score (%) 1.85 ± 0.89 1.72 ± 0.84 0.05 1.84 ± 1.65 1.36 ± 0.90 0.08
Race (%)† 0.99 0.98
White 305 (87.6) 305 (87.6) 184 (78.3) 184 (78.3)
Black 21 (6.0) 21 (6.0) 36 (15.3) 35 (14.9)
Other 22 (6.3) 22 (6.3) 15 (6.4) 16 (6.8)
Smoking (%) 0.11 0.72
Never 158 (46.1) 186 (54.1) 129 (55.1) 126 (53.6)
Past 155 (45.2) 131 (38.1) 87 (37.2) 86 (36.6)
Current 30 (8.7) 27 (7.8) 18 (7.7) 23 (9.8)
Family history of breast cancer (%) 0.006 0.23
Yes 79 (24.0) 50 (15.2) 52 (23.5) 42 (18.5)
No 250 (76.0) 280 (84.8) 169 (76.5) 185 (81.5)
*P-values are significance levels from Student’s t-test and chi-square tests of no difference between cases and controls for continuous and categorical variables.
†Matching variables in control selection. BMI, body mass index; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate.
Table 2 Geometric mean and 95% confidence interval for sex hormone concentrations, separately for placebo and
active randomization groups for breast cancer cases and controls from the Women’s Health Initiative CEE +MPA trial
CEE +MPA trial
Placebo Active treatment
Cases Controls P-value* Cases Controls P-value*
Estradiol (pg/ml)
Baseline 11.97 (4.96, 28.84) 10.05 (4.36, 23.17) 0.001 10.90 (4.83, 24.59) 10.89 (4.19, 28.34) 0.99
Year 1 10.12 (3.56, 28.71) 8.46 (2.86, 25.02) 0.008 22.30 (7.88, 63.06) 20.78 (6.02, 71.72) 0.28
Bioavailable estradiol (pg/ml)
Baseline 8.02 (2.89, 22.25) 6.47 (2.49, 16.85) 0.001 7.10 (2.71, 18.60) 7.00 (2.31, 21.16) 0.82
Year 1 6.75 (2.16, 21.06) 5.35 (1.52, 18.76) 0.002 9.95 (3.75, 26.38) 9.98 (3.14, 31.71) 0.96
Estrone (pg/ml)
Baseline 41.81 (17.36, 95.94) 35.20 (14.99, 82.68) 0.007 36.95 (16.06, 85.03) 36.37 (15.79, 83.74) 0.74
Year 1 37.68 (13.99, 101.49) 34.39 (13.78, 85.81) 0.14 117.48 (30.97, 445.66) 103.96 (23.00, 469.86) 0.14
Estrone sulfate (ng/ml) baseline 0.84 0.79 0.26 0.82 0.80 0.65
(0.37, 1.91) (0.33, 1.88) (0.33, 2.08) (0.29, 2.18)
Year 1 0.75 (0.34, 1.67) 0.69 (0.30, 1.59) 0.17 1.88 (0.61, 5.81) 1.77 (0.51, 6.14) 0.37
SHBG (Nmol/L)
Baseline 36.93 (15.05, 90.63) 41.94 (17.28, 101.80) 0.02 40.49 (14.99, 109.42) 39.81 (14.63, 108.31) 0.76
Year 1 37.37 (14.22, 98.23) 41.86 (16.51, 106.11) 0.06 95.46 (31.96, 285.11) 90.07 (30.96, 262.06) 0.35
Samples are excluded if changes from baseline to year 1 log-transformed concentrations are outside the interquartile range by twice its width.
*P-value from Student’s t-test comparison of case versus control values. CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; SHBG, sex
hormone binding globulin.
Zhao et al. Breast Cancer Research 2014, 16:R30 Page 4 of 9
http://breast-cancer-research.com/content/16/2/R30
Table 3 Geometric mean and 95% confidence interval for sex hormone concentrations, separately for placebo and
active randomization groups for breast cancer cases and controls from the Women’s Health Initiative CEE trial
CEE trial
Placebo Active treatment
Cases Controls P-value* Cases Controls P-value*
Estradiol (pg/ml)
Baseline 12.36 (5.59, 27.38) 10.56 (4.36, 25.57) 0.01 12.72 (3.88, 41.67) 10.43 (4.30, 25.32) 0.01
Year 1 10.31 (3.55, 29.94) 9.37 (3.64, 24.14) 0.21 26.47 (7.89, 88.76) 23.96 (6.77, 84.84) 0.27
Bioavailable estradiol (pg/ml)
Baseline 8.53 (3.41, 21.33) 6.76 (2.59, 17.65) 0.001 8.74 (2.53, 30.20) 6.54 (2.27, 18.84) 0.001
Year 1 6.99 (2.29, 21.28) 6.05 (2.21, 16.57) 0.08 12.33 (3.66, 41.57) 10.21 (3.26, 32.02) 0.03
Estrone (pg/ml)
Baseline 41.05 (17.54, 96.08) 36.23 (15.48, 84.79) 0.05 41.25 (16.66, 102.15) 36.44 (15.66, 84.80) 0.05
Year 1 38.54 (14.68, 101.17) 33.70 (12.06, 94.13) 0.08 124.39 (31.09, 497.59) 134.65 (30.72, 590.11) 0.44
Estrone sulfate (ng/ml)
Baseline 0.86 (0.41, 1.81) 0.77 (0.33, 1.79) 0.07 0.80 (0.29, 2.20) 0.77 (0.35, 1.69) 0.59
Year 1 0.76 (0.51, 1.49) 0.62 (0.43, 1.49) 0.001 1.68 (0.65, 6.84) 1.70 (0.69, 7.06) 0.94
SHBG (Nmol/L)
Baseline 34.11 (14.47, 80.39) 39.99 (15.30, 104.52) 0.02 34.05 (13.11, 88.43) 42.79 (15.19, 120.50) 0.002
Year 1 34.54 (15.30, 77.95) 40.86 (15.73, 106.12) 0.01 82.34 (24.57, 276.00) 99.61 (28.47, 348.54) 0.03
Samples are excluded if changes from baseline to year 1 log-transformed concentrations are outside the interquartile range by twice its width.
*P-value from Student’s t-test comparison of case versus control values. CEE, conjugated equine estrogens; SHBG, sex hormone binding globulin.
Table 4 Odds ratios (95% confidence intervals (CI)) for a
doubling of baseline sex hormone levels in the randomized
placebo and active treatment groups of the Women’s
Health Initiative postmenopausal hormone therapy trials
Odds ratio (95% CI) Numbers of
cases/controlsPlacebo Active
CEE +MPA trial*
Estradiol 2.00 (1.24, 3.21) 0.96 (0.66, 1.40) 276/314
Bioavailable estradiol 1.98 (1.27, 3.07) 1.01 (0.72, 1.43) 265/299
Estrone 1.77 (1.15, 2.73) 1.07 (0.74, 1.56) 273/313
Estrone sulfate 1.18 (0.78, 1.80) 1.08 (0.78, 1.49) 245/287
SHBG* 0.75 (0.51, 1.12) 1.14 (0.82, 1.59) 274/323
CEE trial*
Estradiol 1.50 (0.85, 2.65) 1.31 (0.88, 1.97) 172/207
Bioavailable estradiol 1.69 (0.99, 2.87) 1.58 (1.06, 2.36) 169/203
Estrone 1.28 (0.78, 2.10) 1.31 (0.83, 2.07) 186/216
Estrone sulfate 1.58 (0.91, 2.73) 1.05 (0.65, 1.70) 160/184
SHBG* 0.65 (0.39, 1.08) 0.61 (0.40, 0.92) 178/208
*CEE +MPA, conjugated equine estrogens plus medroxyprogesterone acetate;
CEE, conjugated equine estrogens; SHBG, sex hormone binding globulin.
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verse association of baseline SHBG, with disease risk.
These same patterns prevail in the active treatment
group in the CEE trial. In contrast, these patterns are
not at all evident in the active treatment group in the
CEE +MPA trial, suggesting that the use of CEE +MPA
overrides the expected associations of baseline sex hor-
mone concentrations with breast cancer risk.
Table 4 presents a refined version of the baseline sex
hormone associations with breast cancer in the two HT
trials. Odds ratios for a two-fold increment in baseline
sex hormone level are presented from logistic regression
analyses that control for various breast cancer risk fac-
tors (see Methods), in separate analyses for each analyte.
Positive associations with most baseline estrogens and
an inverse association with SHBG are evident in the pla-
cebo groups and in the active treatment group in the
CEE trial. However, these associations are not evident in
the active treatment group in the CEE +MPA trial.
Table 5 examines the ability of sex hormone changes
from baseline to year 1 following randomization to me-
diate the divergent effects of the two hormone therapy
regimens on breast cancer incidence. Odds ratios for a
two-fold increment in baseline sex hormones are pre-
sented, along with odds ratios for a two-fold increment
(‘change’) from baseline to year 1. The upper part of
Table 5 includes bioavailable estradiol and SHBG jointly,
while the lower part includes the other four serum estrogen
measures simultaneously along with SHBG (bioavailableestradiol is calculated from the other measures and can not
be included with them). The two parts of the Table provide
a similar message: inclusion of the baseline to year 1 sex
hormone changes in the regression model has little impact
on the treatment odds ratio for CEE +MPA, but doing so
appreciably increases the treatment OR for CEE toward the
Table 5 Odds ratios (95% confidence intervals (CI)) for hormone therapy treatment assignment, and for a doubling of
baseline sex hormone and for a doubling from baseline to year 1 of sex hormone values in the Women’s Health
Initiative postmenopausal hormone therapy trials
Odds ratio (95% confidence interval)
CEE +MPA trial* CEE trial*
Baseline only† Baseline + year 1† Baseline only Baseline + year 1
Treatment 1.58 (1.13, 2.22) 1.46 (0.86, 2.47) 0.62 (0.40, 0.96) 0.84 (0.43, 1.65)
Baseline:
Bioavailable estradiol 1.41 (1.03, 1.93) 1.44 (1.03, 2.01) 1.31 (0.93, 1.84) 1.24 (0.86, 1.79
SHBG* 1.11 (0.83, 1.50) 1.13 (0.83, 1.53) 0.67 (0.47, 0.97) 0.64 (0.44, 0.83)
Baseline to year 1 change:
Bioavailable estradiol 1.05 (0.81, 1.36) 0.87 (0.62, 1.23)
SHBG 1.04 (0.76, 1.43) 0.85 (0.57, 1.26)
Cases/controls 254/291 254/291 161/191 161/191
CEE +MPA trial CEE trial
Baseline only Baseline + year 1 Baseline only Baseline + year 1
Treatment 1.59 (1.10, 2.30) 1.65 (0.92, 2.97) 0.71 (0.43, 1.15) 0.92 (0.41, 2.09)
Baseline:
Estradiol 1.22 (0.71, 1.76) 1.22 (0.71, 2.08) 1.56 (0.90, 2.71) 1.87 (0.97, 3.62)
Estrone 1.28 (0.82, 2.01) 1.20 (0.72, 2.02) 0.78 (0.43, 1.40) 0.57 (0.29, 1.12)
Estrone sulfate 0.95 (0.69, 1.30) 0.93 (0.66, 1.31) 1.09 (0.69, 1.73) 1.25 (0.76, 2.05)
SHBG 0.92 (0.69, 1.23) 0.92 (0.67, 1.25) 0.56 (0.38, 0.83) 0.60 (0.39, 0.90)
Baseline to year 1 change:
Estradiol 1.11 (0.79, 1.56) 1.18 (0.71, 1.96)
Estrone 0.95 (0.65, 1.39) 0.57 (0.35, 0.95)
Estrone sulfate 0.94 (0.65, 1.37) 1.50 (0.91, 2.48)
SHBG 1.00 (0.66, 1.50) 1.00 (0.56, 1.79)
Cases/controls 230/248 230/248 147/151 147/151
*CEE +MPA, conjugated equine estrogens plus medroxyprogesterone acetate; CEE, conjugated equine estrogens; SHBG, sex hormone binding globulin.
†For each trial the left column gives odds ratios and 95% confidence intervals when only baseline variables are included, while the right column adds
corresponding year 1 variables in the analysis. Hormone therapy mediation is indicated by treatment odds ratios that move substantially toward the null when
the year 1 sex hormone data are included.
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the baseline to year 1 change variables in the analysis moves
the estimated CEE +MPA treatment OR slightly away from
the null, from 1.59 to 1.65, whereas the estimated CEE
treatment OR moves substantially toward the null, from
0.71 to 0.92. While the upper part of Table 5 suggests that
the SHBG increase with CEE may compensate somewhat
for corresponding serum estrogen increases, the more de-
tailed analysis in the lower part of Table 5 suggests that
women having relatively large increases in serum estrone
with CEE are at reduced breast cancer risk.
Discussion
These analyses provide insight into the divergent breast
cancer findings with CEE +MPA versus CEE in the WHI
randomized, controlled trials. Specifically, women at a
relatively low baseline breast cancer risk in the CEE trial
continue at low risk if assigned to active treatment.Furthermore, the configuration of sex hormone changes
among women assigned to active CEE provides an ex-
planation for much of the observed breast cancer risk
reduction (Table 5).
In sharp contrast, there is no evidence for any associ-
ation between baseline sex hormone levels and breast
cancer risk among women assigned to active treatment
in the CEE +MPA trial, whereas associations are appar-
ent in the placebo group (Table 4). Moreover, breast
cancer risk does not relate to changes in sex hormones
from baseline to year 1 in the CEE +MPA trial (Table 5).
Evidently, in the presence of 2.5 mg/d medroxyproges-
terone acetate, these risk variations are quite unimport-
ant. Women having a favorable serum sex hormone
profile, perhaps from years of good diet and activity pat-
terns and normal weight maintenance, evidently have
similar elevated breast cancer risk to those having an un-
favorable serum sex hormone profile. These observations
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action between baseline sex hormone levels and CEE +
MPA odds ratios [13].
The analyses presented here excluded about 10 to 15%
of placebo group, and about 5% of active treatment group
cases and controls based on an IQR outlier criterion as ap-
plied to the differences between baseline and one-year
log-analyte concentrations. These exclusion rates are con-
sistent with a poor correspondence between split sample
quality control specimens for about 10% of samples, espe-
cially at low sex hormone concentrations. To ensure that
our outlier exclusion method was not unduly influencing
results, the Tables 2, 3, 4 and 5 analyses were repeated
using Rosner’s [20] ‘many-outlier detection procedure’,
which relies on departure from normality. This method
resulted in fewer outlier exclusions, about 2 to 4% in the
placebo groups and almost none in the active treatment
groups. The analytic results with this less restrictive out-
lier detection approach were quite similar to those shown
in Tables 2, 3, 4 and 5. A modest difference arose in the
Table 5 analysis where the HR (95% CI) for a doubling of
estrone from baseline to one-year was 0.68 (0.44, 1.05), as
compared to 0.57 (0.35, 0.95) in Table 5.
The mechanisms whereby MPA would have such a
dominant effect on breast cancer risk remain to be eluci-
dated. MPA is a potent progestin with high affinity for
progesterone and androgen receptors, and with little es-
trogen receptor affinity. It circulates in a form that is 88%
bound to albumin, and is not bound by SHBG [21]. MPA
could exert direct intracellular effects on division rates of
breast ductal epithelial cells in a manner that achieves a
high cell division rate regardless of the other sex hormone
concentrations. A related possibility is that MPA sensitizes
the proliferative response to low doses of estradiol [13].
The analyses presented here suggest that the collective
changes in sex hormones with CEE contribute strongly to
the observed breast cancer risk reduction [5-7] in the
WHI trial. It is plausible that the roughly two-fold increase
in SHBG with CEE substantially offsets the corresponding
large increase in serum estrogens in their effects on breast
ductal epithelial cells. The upper portion of Table 5 pro-
vides some modest support for this line of reasoning, and
may raise concerns about potential breast cancer risks
with the trend toward use of transdermal estradiol, which
does not materially increase SHBG in a first-pass hepatic
effect, but substantially increases serum estradiol. More-
over, both oral and transdermal estradiols increase serum
estradiol to a greater extent than does CEE.
The detailed analyses shown in the lower portion of
Table 5 suggest that an additional mechanism may be at
play with CEE. Specifically, women having a relatively
large estrone increase with CEE use have a reduced (P =
0.03) breast cancer risk. This observation could align with
the intriguing hypothesis that estrogen exposure followinga sufficient period of estrogen deprivation induces apop-
tosis of nascent breast tumor cells [22]. Note, however,
that the increases in SHBG and serum estrogens with
CEE use are highly correlated (for example, correlations
(95% CIs) of 0.73 (0.66, 0.79) between (log-transformed)
estradiol and estrone changes; and 0.59 (0.59, 0.67) be-
tween estrone and SHBG changes in the control group
women) making it challenging to distinguish among the
changes in specific sex hormones in relation to breast
cancer risk. The fact that the estrone change stands out
in Table 5, in spite of these statistical challenges, is in-
teresting and merits replication in other settings.
The strengths of this study are the randomized, con-
trolled design of the WHI hormone therapy trials of ad-
equate size, the quality sex hormone data assessment, and
the ability to study CEE and CEE +MPA results side-by-
side. Weaknesses include the absence of measurements
on the biological changes resulting from the use of MPA.Conclusions
In summary, post-treatment changes in serum estrogens
and SHBG concentrations, or changes in the association of
such concentrations with disease risk, have the potential to
substantially explain both the elevation in breast cancer risk
with CEE +MPA and the reduction in risk with CEE. The
CEE data suggest that a roughly two-fold increase in SHBG
may offset risk that may otherwise attend corresponding
major serum estrogen increases, and also support the ob-
servation [9] that estrogen exposure following a sustained
period of estrogen deprivation reduces risk [22]. However,
when MPA is added to the hormone therapy regimen, the
risk variations otherwise associated with these sex hormone
levels are no longer evident, and an important increase in
breast cancer risk follows, especially among women who
would otherwise be at relatively low risk. Whether different
formulations or routes of delivery of HT will provide simi-
lar results is unknown and also warrants further study.
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